A phase 1b single-arm trial of intratumoral oncolytic virus V937 in combination with pembrolizumab in patients with advanced melanoma: results from the CAPRA study
Background CAPRA (NCT02565992) evaluated Coxsackievirus A21 (V937) + pembrolizumab for metastatic/unresectable stage IIIB–IV melanoma. Methods Patients received intratumoral V937 on days 1, 3, 5, and 8 (then every 3 weeks [Q3W]) and intravenous pembrolizumab 2 mg/kg Q3W from day 8. Primary endpoint...
Gespeichert in:
| Veröffentlicht in: | Cancer Immunology, Immunotherapy Immunotherapy, 2023-06, Vol.72 (6), p.1405-1415 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1415 |
|---|---|
| container_issue | 6 |
| container_start_page | 1405 |
| container_title | Cancer Immunology, Immunotherapy |
| container_volume | 72 |
| creator | Silk, Ann W. O’Day, Steven J. Kaufman, Howard L. Bryan, Jennifer Norrell, Jacqueline T. Imbergamo, Casey Portal, Daniella Zambrano-Acosta, Edwin Palmeri, Marisa Fein, Seymour Wu, Cai Guerreiro, Leslie Medina, Daniel Bommareddy, Praveen K. Zloza, Andrew Fox, Bernard A. Ballesteros-Merino, Carmen Ren, Yixin Shafren, Darren Grose, Mark Vieth, Joshua A. Mehnert, Janice M. |
| description | Background
CAPRA (NCT02565992) evaluated Coxsackievirus A21 (V937) + pembrolizumab for metastatic/unresectable stage IIIB–IV melanoma.
Methods
Patients received intratumoral V937 on days 1, 3, 5, and 8 (then every 3 weeks [Q3W]) and intravenous pembrolizumab 2 mg/kg Q3W from day 8. Primary endpoint was safety.
Results
Median time from first dose to data cutoff was 32.0 months. No dose-limiting toxicities occurred; 14% (5/36) of patients experienced grade 3‒5 treatment-related adverse events. Objective response rate was 47% (complete response, 22%). Among 17 responders, 14 (82%) had responses ≥ 6 months. Among 8 patients previously treated with immunotherapy, 3 responded (1 complete, 2 partial). Responses were associated with increased serum CXCL10 and CCL22, suggesting viral replication contributes to antitumor immunity. For responders versus nonresponders, there was no difference in baseline tumor PD-L1 expression,
ICAM1
expression, or CD3
+
infiltrates. Surprisingly, the baseline cell density of CD3
+
CD8
−
T cells in the tumor microenvironment was significantly lower in responders compared with nonresponders (
P
= 0.0179).
Conclusions
These findings suggest responses to this combination may be seen even in patients without a typical “immune-active” microenvironment.
Trial registration number
NCT02565992. |
| doi_str_mv | 10.1007/s00262-022-03314-1 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10198910</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2815843086</sourcerecordid><originalsourceid>FETCH-LOGICAL-c475t-43858cb1627049ba5acc50e015657d78e17b58440514cd671d2ebed8b31406ee3</originalsourceid><addsrcrecordid>eNp9UU2PFCEQJUbjjqt_wIMh8dxaNNAfXsxk4leyicaoVwJ0zQybbhiBHjP-Hf-ojL2uevFAoPJevVfFI-Qxg2cMoH2eAOqmrqAuh3MmKnaHrJjgpewku0tWwAVULYC4IA9Sui6PGvr-PrngjRBSMFiRH2t62OuElBmanN-NWOk40RydHmnYUudz1HmeQjzX3obxlJ2lRxfnRL_0vC0MasNknNfZBU-_ubynB5xMDKP7Pk_anBmHAqLPaYH1cNTe4kAnHLUPk35BI6Z5LPg2huK-R7pZf_i4pinPw-khubfVY8JHN_cl-fz61afN2-rq_Zt3m_VVZUUrcyV4JztrWFO3IHqjpbZWAgKTjWyHtkPWGtkJAZIJOzQtG2o0OHSmfB00iPySvFx0D7OZcLB43n1Uh-gmHU8qaKf-Rbzbq104Kgas73oGReHpjUIMX2dMWV2HOfoytKo7Vsw5dE1h1QvLxpBSxO2tBQN1TlYtyaqSrPqVrGKl6cnfw922_I6yEPhCSAXyO4x_vP8j-xMPq7El</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2815843086</pqid></control><display><type>article</type><title>A phase 1b single-arm trial of intratumoral oncolytic virus V937 in combination with pembrolizumab in patients with advanced melanoma: results from the CAPRA study</title><source>MEDLINE</source><source>SpringerLink Journals (MCLS)</source><source>PubMed Central</source><creator>Silk, Ann W. ; O’Day, Steven J. ; Kaufman, Howard L. ; Bryan, Jennifer ; Norrell, Jacqueline T. ; Imbergamo, Casey ; Portal, Daniella ; Zambrano-Acosta, Edwin ; Palmeri, Marisa ; Fein, Seymour ; Wu, Cai ; Guerreiro, Leslie ; Medina, Daniel ; Bommareddy, Praveen K. ; Zloza, Andrew ; Fox, Bernard A. ; Ballesteros-Merino, Carmen ; Ren, Yixin ; Shafren, Darren ; Grose, Mark ; Vieth, Joshua A. ; Mehnert, Janice M.</creator><creatorcontrib>Silk, Ann W. ; O’Day, Steven J. ; Kaufman, Howard L. ; Bryan, Jennifer ; Norrell, Jacqueline T. ; Imbergamo, Casey ; Portal, Daniella ; Zambrano-Acosta, Edwin ; Palmeri, Marisa ; Fein, Seymour ; Wu, Cai ; Guerreiro, Leslie ; Medina, Daniel ; Bommareddy, Praveen K. ; Zloza, Andrew ; Fox, Bernard A. ; Ballesteros-Merino, Carmen ; Ren, Yixin ; Shafren, Darren ; Grose, Mark ; Vieth, Joshua A. ; Mehnert, Janice M.</creatorcontrib><description>Background
CAPRA (NCT02565992) evaluated Coxsackievirus A21 (V937) + pembrolizumab for metastatic/unresectable stage IIIB–IV melanoma.
Methods
Patients received intratumoral V937 on days 1, 3, 5, and 8 (then every 3 weeks [Q3W]) and intravenous pembrolizumab 2 mg/kg Q3W from day 8. Primary endpoint was safety.
Results
Median time from first dose to data cutoff was 32.0 months. No dose-limiting toxicities occurred; 14% (5/36) of patients experienced grade 3‒5 treatment-related adverse events. Objective response rate was 47% (complete response, 22%). Among 17 responders, 14 (82%) had responses ≥ 6 months. Among 8 patients previously treated with immunotherapy, 3 responded (1 complete, 2 partial). Responses were associated with increased serum CXCL10 and CCL22, suggesting viral replication contributes to antitumor immunity. For responders versus nonresponders, there was no difference in baseline tumor PD-L1 expression,
ICAM1
expression, or CD3
+
infiltrates. Surprisingly, the baseline cell density of CD3
+
CD8
−
T cells in the tumor microenvironment was significantly lower in responders compared with nonresponders (
P
= 0.0179).
Conclusions
These findings suggest responses to this combination may be seen even in patients without a typical “immune-active” microenvironment.
Trial registration number
NCT02565992.</description><identifier>ISSN: 0340-7004</identifier><identifier>EISSN: 1432-0851</identifier><identifier>DOI: 10.1007/s00262-022-03314-1</identifier><identifier>PMID: 36445410</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Animals ; Antibodies, Monoclonal, Humanized - adverse effects ; Cancer Research ; CCL22 protein ; CD3 antigen ; CD8 antigen ; Cell density ; CXCL10 protein ; Goats ; Humans ; Immunology ; Immunotherapy ; Intercellular adhesion molecule 1 ; Lymphocytes T ; Medicine ; Medicine & Public Health ; Melanoma ; Melanoma - drug therapy ; Metastases ; Oncology ; Oncolysis ; Oncolytic Viruses ; PD-L1 protein ; Pembrolizumab ; Tumor Microenvironment ; Tumors</subject><ispartof>Cancer Immunology, Immunotherapy, 2023-06, Vol.72 (6), p.1405-1415</ispartof><rights>The Author(s) 2022</rights><rights>2022. The Author(s).</rights><rights>The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c475t-43858cb1627049ba5acc50e015657d78e17b58440514cd671d2ebed8b31406ee3</citedby><cites>FETCH-LOGICAL-c475t-43858cb1627049ba5acc50e015657d78e17b58440514cd671d2ebed8b31406ee3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10198910/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10198910/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,41488,42557,51319,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36445410$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Silk, Ann W.</creatorcontrib><creatorcontrib>O’Day, Steven J.</creatorcontrib><creatorcontrib>Kaufman, Howard L.</creatorcontrib><creatorcontrib>Bryan, Jennifer</creatorcontrib><creatorcontrib>Norrell, Jacqueline T.</creatorcontrib><creatorcontrib>Imbergamo, Casey</creatorcontrib><creatorcontrib>Portal, Daniella</creatorcontrib><creatorcontrib>Zambrano-Acosta, Edwin</creatorcontrib><creatorcontrib>Palmeri, Marisa</creatorcontrib><creatorcontrib>Fein, Seymour</creatorcontrib><creatorcontrib>Wu, Cai</creatorcontrib><creatorcontrib>Guerreiro, Leslie</creatorcontrib><creatorcontrib>Medina, Daniel</creatorcontrib><creatorcontrib>Bommareddy, Praveen K.</creatorcontrib><creatorcontrib>Zloza, Andrew</creatorcontrib><creatorcontrib>Fox, Bernard A.</creatorcontrib><creatorcontrib>Ballesteros-Merino, Carmen</creatorcontrib><creatorcontrib>Ren, Yixin</creatorcontrib><creatorcontrib>Shafren, Darren</creatorcontrib><creatorcontrib>Grose, Mark</creatorcontrib><creatorcontrib>Vieth, Joshua A.</creatorcontrib><creatorcontrib>Mehnert, Janice M.</creatorcontrib><title>A phase 1b single-arm trial of intratumoral oncolytic virus V937 in combination with pembrolizumab in patients with advanced melanoma: results from the CAPRA study</title><title>Cancer Immunology, Immunotherapy</title><addtitle>Cancer Immunol Immunother</addtitle><addtitle>Cancer Immunol Immunother</addtitle><description>Background
CAPRA (NCT02565992) evaluated Coxsackievirus A21 (V937) + pembrolizumab for metastatic/unresectable stage IIIB–IV melanoma.
Methods
Patients received intratumoral V937 on days 1, 3, 5, and 8 (then every 3 weeks [Q3W]) and intravenous pembrolizumab 2 mg/kg Q3W from day 8. Primary endpoint was safety.
Results
Median time from first dose to data cutoff was 32.0 months. No dose-limiting toxicities occurred; 14% (5/36) of patients experienced grade 3‒5 treatment-related adverse events. Objective response rate was 47% (complete response, 22%). Among 17 responders, 14 (82%) had responses ≥ 6 months. Among 8 patients previously treated with immunotherapy, 3 responded (1 complete, 2 partial). Responses were associated with increased serum CXCL10 and CCL22, suggesting viral replication contributes to antitumor immunity. For responders versus nonresponders, there was no difference in baseline tumor PD-L1 expression,
ICAM1
expression, or CD3
+
infiltrates. Surprisingly, the baseline cell density of CD3
+
CD8
−
T cells in the tumor microenvironment was significantly lower in responders compared with nonresponders (
P
= 0.0179).
Conclusions
These findings suggest responses to this combination may be seen even in patients without a typical “immune-active” microenvironment.
Trial registration number
NCT02565992.</description><subject>Animals</subject><subject>Antibodies, Monoclonal, Humanized - adverse effects</subject><subject>Cancer Research</subject><subject>CCL22 protein</subject><subject>CD3 antigen</subject><subject>CD8 antigen</subject><subject>Cell density</subject><subject>CXCL10 protein</subject><subject>Goats</subject><subject>Humans</subject><subject>Immunology</subject><subject>Immunotherapy</subject><subject>Intercellular adhesion molecule 1</subject><subject>Lymphocytes T</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Melanoma</subject><subject>Melanoma - drug therapy</subject><subject>Metastases</subject><subject>Oncology</subject><subject>Oncolysis</subject><subject>Oncolytic Viruses</subject><subject>PD-L1 protein</subject><subject>Pembrolizumab</subject><subject>Tumor Microenvironment</subject><subject>Tumors</subject><issn>0340-7004</issn><issn>1432-0851</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp9UU2PFCEQJUbjjqt_wIMh8dxaNNAfXsxk4leyicaoVwJ0zQybbhiBHjP-Hf-ojL2uevFAoPJevVfFI-Qxg2cMoH2eAOqmrqAuh3MmKnaHrJjgpewku0tWwAVULYC4IA9Sui6PGvr-PrngjRBSMFiRH2t62OuElBmanN-NWOk40RydHmnYUudz1HmeQjzX3obxlJ2lRxfnRL_0vC0MasNknNfZBU-_ubynB5xMDKP7Pk_anBmHAqLPaYH1cNTe4kAnHLUPk35BI6Z5LPg2huK-R7pZf_i4pinPw-khubfVY8JHN_cl-fz61afN2-rq_Zt3m_VVZUUrcyV4JztrWFO3IHqjpbZWAgKTjWyHtkPWGtkJAZIJOzQtG2o0OHSmfB00iPySvFx0D7OZcLB43n1Uh-gmHU8qaKf-Rbzbq104Kgas73oGReHpjUIMX2dMWV2HOfoytKo7Vsw5dE1h1QvLxpBSxO2tBQN1TlYtyaqSrPqVrGKl6cnfw922_I6yEPhCSAXyO4x_vP8j-xMPq7El</recordid><startdate>20230601</startdate><enddate>20230601</enddate><creator>Silk, Ann W.</creator><creator>O’Day, Steven J.</creator><creator>Kaufman, Howard L.</creator><creator>Bryan, Jennifer</creator><creator>Norrell, Jacqueline T.</creator><creator>Imbergamo, Casey</creator><creator>Portal, Daniella</creator><creator>Zambrano-Acosta, Edwin</creator><creator>Palmeri, Marisa</creator><creator>Fein, Seymour</creator><creator>Wu, Cai</creator><creator>Guerreiro, Leslie</creator><creator>Medina, Daniel</creator><creator>Bommareddy, Praveen K.</creator><creator>Zloza, Andrew</creator><creator>Fox, Bernard A.</creator><creator>Ballesteros-Merino, Carmen</creator><creator>Ren, Yixin</creator><creator>Shafren, Darren</creator><creator>Grose, Mark</creator><creator>Vieth, Joshua A.</creator><creator>Mehnert, Janice M.</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>5PM</scope></search><sort><creationdate>20230601</creationdate><title>A phase 1b single-arm trial of intratumoral oncolytic virus V937 in combination with pembrolizumab in patients with advanced melanoma: results from the CAPRA study</title><author>Silk, Ann W. ; O’Day, Steven J. ; Kaufman, Howard L. ; Bryan, Jennifer ; Norrell, Jacqueline T. ; Imbergamo, Casey ; Portal, Daniella ; Zambrano-Acosta, Edwin ; Palmeri, Marisa ; Fein, Seymour ; Wu, Cai ; Guerreiro, Leslie ; Medina, Daniel ; Bommareddy, Praveen K. ; Zloza, Andrew ; Fox, Bernard A. ; Ballesteros-Merino, Carmen ; Ren, Yixin ; Shafren, Darren ; Grose, Mark ; Vieth, Joshua A. ; Mehnert, Janice M.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c475t-43858cb1627049ba5acc50e015657d78e17b58440514cd671d2ebed8b31406ee3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Animals</topic><topic>Antibodies, Monoclonal, Humanized - adverse effects</topic><topic>Cancer Research</topic><topic>CCL22 protein</topic><topic>CD3 antigen</topic><topic>CD8 antigen</topic><topic>Cell density</topic><topic>CXCL10 protein</topic><topic>Goats</topic><topic>Humans</topic><topic>Immunology</topic><topic>Immunotherapy</topic><topic>Intercellular adhesion molecule 1</topic><topic>Lymphocytes T</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Melanoma</topic><topic>Melanoma - drug therapy</topic><topic>Metastases</topic><topic>Oncology</topic><topic>Oncolysis</topic><topic>Oncolytic Viruses</topic><topic>PD-L1 protein</topic><topic>Pembrolizumab</topic><topic>Tumor Microenvironment</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Silk, Ann W.</creatorcontrib><creatorcontrib>O’Day, Steven J.</creatorcontrib><creatorcontrib>Kaufman, Howard L.</creatorcontrib><creatorcontrib>Bryan, Jennifer</creatorcontrib><creatorcontrib>Norrell, Jacqueline T.</creatorcontrib><creatorcontrib>Imbergamo, Casey</creatorcontrib><creatorcontrib>Portal, Daniella</creatorcontrib><creatorcontrib>Zambrano-Acosta, Edwin</creatorcontrib><creatorcontrib>Palmeri, Marisa</creatorcontrib><creatorcontrib>Fein, Seymour</creatorcontrib><creatorcontrib>Wu, Cai</creatorcontrib><creatorcontrib>Guerreiro, Leslie</creatorcontrib><creatorcontrib>Medina, Daniel</creatorcontrib><creatorcontrib>Bommareddy, Praveen K.</creatorcontrib><creatorcontrib>Zloza, Andrew</creatorcontrib><creatorcontrib>Fox, Bernard A.</creatorcontrib><creatorcontrib>Ballesteros-Merino, Carmen</creatorcontrib><creatorcontrib>Ren, Yixin</creatorcontrib><creatorcontrib>Shafren, Darren</creatorcontrib><creatorcontrib>Grose, Mark</creatorcontrib><creatorcontrib>Vieth, Joshua A.</creatorcontrib><creatorcontrib>Mehnert, Janice M.</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>ProQuest Health and Medical</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database (Proquest)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>ProQuest Biological Science Journals</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancer Immunology, Immunotherapy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Silk, Ann W.</au><au>O’Day, Steven J.</au><au>Kaufman, Howard L.</au><au>Bryan, Jennifer</au><au>Norrell, Jacqueline T.</au><au>Imbergamo, Casey</au><au>Portal, Daniella</au><au>Zambrano-Acosta, Edwin</au><au>Palmeri, Marisa</au><au>Fein, Seymour</au><au>Wu, Cai</au><au>Guerreiro, Leslie</au><au>Medina, Daniel</au><au>Bommareddy, Praveen K.</au><au>Zloza, Andrew</au><au>Fox, Bernard A.</au><au>Ballesteros-Merino, Carmen</au><au>Ren, Yixin</au><au>Shafren, Darren</au><au>Grose, Mark</au><au>Vieth, Joshua A.</au><au>Mehnert, Janice M.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A phase 1b single-arm trial of intratumoral oncolytic virus V937 in combination with pembrolizumab in patients with advanced melanoma: results from the CAPRA study</atitle><jtitle>Cancer Immunology, Immunotherapy</jtitle><stitle>Cancer Immunol Immunother</stitle><addtitle>Cancer Immunol Immunother</addtitle><date>2023-06-01</date><risdate>2023</risdate><volume>72</volume><issue>6</issue><spage>1405</spage><epage>1415</epage><pages>1405-1415</pages><issn>0340-7004</issn><eissn>1432-0851</eissn><abstract>Background
CAPRA (NCT02565992) evaluated Coxsackievirus A21 (V937) + pembrolizumab for metastatic/unresectable stage IIIB–IV melanoma.
Methods
Patients received intratumoral V937 on days 1, 3, 5, and 8 (then every 3 weeks [Q3W]) and intravenous pembrolizumab 2 mg/kg Q3W from day 8. Primary endpoint was safety.
Results
Median time from first dose to data cutoff was 32.0 months. No dose-limiting toxicities occurred; 14% (5/36) of patients experienced grade 3‒5 treatment-related adverse events. Objective response rate was 47% (complete response, 22%). Among 17 responders, 14 (82%) had responses ≥ 6 months. Among 8 patients previously treated with immunotherapy, 3 responded (1 complete, 2 partial). Responses were associated with increased serum CXCL10 and CCL22, suggesting viral replication contributes to antitumor immunity. For responders versus nonresponders, there was no difference in baseline tumor PD-L1 expression,
ICAM1
expression, or CD3
+
infiltrates. Surprisingly, the baseline cell density of CD3
+
CD8
−
T cells in the tumor microenvironment was significantly lower in responders compared with nonresponders (
P
= 0.0179).
Conclusions
These findings suggest responses to this combination may be seen even in patients without a typical “immune-active” microenvironment.
Trial registration number
NCT02565992.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>36445410</pmid><doi>10.1007/s00262-022-03314-1</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0340-7004 |
| ispartof | Cancer Immunology, Immunotherapy, 2023-06, Vol.72 (6), p.1405-1415 |
| issn | 0340-7004 1432-0851 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10198910 |
| source | MEDLINE; SpringerLink Journals (MCLS); PubMed Central |
| subjects | Animals Antibodies, Monoclonal, Humanized - adverse effects Cancer Research CCL22 protein CD3 antigen CD8 antigen Cell density CXCL10 protein Goats Humans Immunology Immunotherapy Intercellular adhesion molecule 1 Lymphocytes T Medicine Medicine & Public Health Melanoma Melanoma - drug therapy Metastases Oncology Oncolysis Oncolytic Viruses PD-L1 protein Pembrolizumab Tumor Microenvironment Tumors |
| title | A phase 1b single-arm trial of intratumoral oncolytic virus V937 in combination with pembrolizumab in patients with advanced melanoma: results from the CAPRA study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T10%3A34%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20phase%201b%20single-arm%20trial%20of%20intratumoral%20oncolytic%20virus%20V937%20in%20combination%20with%20pembrolizumab%20in%20patients%20with%20advanced%20melanoma:%20results%20from%20the%20CAPRA%20study&rft.jtitle=Cancer%20Immunology,%20Immunotherapy&rft.au=Silk,%20Ann%20W.&rft.date=2023-06-01&rft.volume=72&rft.issue=6&rft.spage=1405&rft.epage=1415&rft.pages=1405-1415&rft.issn=0340-7004&rft.eissn=1432-0851&rft_id=info:doi/10.1007/s00262-022-03314-1&rft_dat=%3Cproquest_pubme%3E2815843086%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2815843086&rft_id=info:pmid/36445410&rfr_iscdi=true |